Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Medically reviewed by Mary Choy, PharmD Key Takeaways Biologic medications help reduce inflammation in ulcerative colitis. If you're new to biologics, infliximab might be your first option for ...

Guselkumab and risankizumab demonstrated the highest adjusted survival time for effectiveness (RMST, 1.93 years for both; 95% CI, 1.91-1.95 and 1.90-1.96 years, respectively). Risankizumab showed the ...